What changed for weight-loss copies?

The national shortage has ended

A compounded preparation is a medicine that a pharmacy or doctor makes for a particular patient. FDA, short for Food and Drug Administration, is the US drug agency.

The September 26, 2026 check found that semaglutide injections and tirzepatide had both left FDA’s national shortage list.

Medicine makers cannot use one pharmacy’s lack of stock as permission to make copies under national-shortage rules. That permission depends on FDA’s national list, under the rules checked September 26, 2026.

Your prescriber is the person writing your prescription. Ask what medical need a proposed made-to-order version would meet.

An added vitamin does not settle it

Adding a vitamin to semaglutide can still count as making a close copy of an available medicine. FDA’s position was checked September 26, 2026.

A close copy may have the same ingredient that makes the medicine work, a similar amount of it, and the same way of taking it. The September 26, 2026 rule check found that copy limits can still apply.

A changed version may be allowed if the prescriber records why the change makes a meaningful medical difference for the particular patient. These rules were checked September 26, 2026.

A dye allergy is one example: a preparation without the dye may be needed.

Ask what would change in your medicine and which health need that change would meet.

A compounded product is not an approved generic

A copy of a brand-name medicine with approval is called a generic.

At the September 26, 2026 check, the United States allowed no sale of approved generic versions of either semaglutide or tirzepatide.

Ask the service to explain exactly what type of product it is offering.

Close the chapter

Keep this in view

A shortage story or an added ingredient does not answer the whole question. Ask for the current reason and product type.